SecBot SecBot
SECBOTREPLAY Home › Report › OTLK

OTLK · Outlook Therapeutics priced a dilutive underwritten public offering of…

Outlook Therapeutics, Inc. · PRESS-RELEASE filed Aug 12, 2026 at 21:45 ET

At the news

BEARISHIMPACT 7/10

PRESS-RELEASE filed Aug 12, 2026 at 21:45 ET

Outlook Therapeutics priced a dilutive underwritten public offering of 55.6M shares and warrants at $0.99/unit, raising ~$55M gross proceeds to fund the U.S. commercial launch of LYTENAVA. The offering represents massive dilution (~50% of current shares) and comes just as the company disclosed a going-concern cash runway only into September 2026. While the capital infusion extends the runway, the severe dilution and distressed financing context make this bearish.

  • Priced 55,555,556 shares + warrants at $0.99/unit, raising ~$55M gross proceeds
  • Warrants exercisable at $1.10/share, 5-year term, adding further potential dilution
  • Underwriters have 30-day option for up to 8,333,333 additional shares/warrants
  • Proceeds to fund U.S. commercial launch of LYTENAVA and working capital

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access